Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling Lunasin is a promising chemopreventive agent. The objective was to study the effect of lunasin on human colon cancer metastasis using in vitro and in vivo colon cancer model of liver metastasis. Lunasin inhibited the activation of focal adhesion kinase by 28%, 39% and 60% in RKO, HCT-116 and KM12L4 human colon cancer cells, respectively. Lunasin caused an increase in the expression of the inhibitor of kappa B alpha, a decrease in nuclear p50 NF-kB and a reduction in the migration of cancer cells. Lunasin inhibited metastasis and potentiated the effect of oxaliplatin by reducing the expression of proliferating cell nuclear antigen. Liver metastatic nodules were reduced from 28 (PBS) to 14 (lunasin, p = 0.047) while combination of lunasin and oxaliplatin to 5 (p = 0.004). The tumor burden was reduced from 0.13 (PBS) to 0.10 (lunasin, p = 0.039) to 0.04 (lunasin-oxaliplatin, p less than 0.0001). The effect of oxaliplatin in modifying the expression of proteins involved in apoptosis and metastasis was potentiated by lunasin. Lunasin inhibited metastasis by direct binding with alpha-5 beta-1 integrin suppressing FAK/ERK/NF-kB signaling, and potentiated the effect of oxaliplatin in preventing the outgrowth of metastasis.
Cancer Community At Illinois Symposium 2012 April 5-6, 2012: Connecting patient care, research, and scientific advancement Symposium Premise This on-campus research symposium aims to bring together members of campus and the surrounding community to foster interdisciplinary discussions on cancer research and its affects on patient care. In order to increase understanding and awareness, we will discuss in an open forum with research talks, poster presentations, and panel discussions. We invite community members, clinicians, and researchers from UIUC and other Midwest regional institutions from departments ranging from the social sciences to basic sciences to engineering and medicine. The symposium features invited talks from nationally-recognized cancer researchers, oral presentations from UIUC faculty and students, and poster sessions. We encourage student researchers from UIUC and from other regional schools to apply (travel awards are available). About CC@I Symposium The Cancer Community at Illinois (CC@I) Symposium is organized by a group of students on the University of Illinois campus to bridge the areas of social science, basic sciences to engineering and medicine as they relate to cancer. The symposium mission is to: 1) Facilitate interdisciplinary collaboration and understanding that transcends established departmental affiliation; 2) Foster an increased understanding of the social and environmental factors affecting patients; and 3) Develop unique vantage points afforded by interactive dialogue between and among the various cancer research disciplines. In order to accomplish this, the symposium will engage the local patient community through use of the nascent social and support efforts of the Mills Breast Cancer Institute, Carle Hospital, and regional clinical collaborators. If you are interested in other CC@I events or the program in general, please contact firstname.lastname@example.org
-From Dr. de Mejia's faculty profile
The Focal Point Project by the Graduate College
Cite this work
Researchers should cite this work as follows:
Elvira de Mejia (2012), "[Illinois] Cancer Community Symposium 2012: Arginine Glycine Aspartic Acid Motif Peptide Potentiates the Effect of Oxaliplatin Preventing Colon Cancer Metastasis, Binds to α5 β1 Integrin and Suppresses FAK/ERK/NF-kB Signaling," https://nanohub.org/resources/13942.
Beckman Institute, University of Illinois at Urbana-Champaign, Urbana, IL